Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
2. Kieffer TL, Finucane MM, Nettles RE, Quinn TC, Broman KW,
Ray SC, et al. Genotypic analysis of HIV-1 drug resistance at the
limit of detection: virus production without evolution in trea-
ted adults with undetectable HIV loads. J Infect Dis 2004;
3. Persaud D, Siberry GK, Ahonkhai A, Kajdas J, Monie D, Hutton
N, et al. Continued production of drug-sensitive human im-
munodeﬁciency virus type 1 in children on combination anti-
retroviral therapy who have undetectable viral loads. J Virol
4. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, et al. HIV
rebounds from latently infected cells, rather than from con-
tinuing low-level replication. Proc Natl Acad Sci U S A 2008;
5. Wiegand A, Cossarini F, Poethke C, Kearney M, Spindler J,
O’shea A, et al. Raltegravir intensiﬁcation does not reduce
persistent HIV-1 viremia in treatment-experienced patients.
17th Conference on Retroviruses and Opportunistic Infections
(CROI 2010); 2010.
6. Joly V, Fagard C, Descamps D, Colin de Verdiere N, Rafﬁ F,
Tabuteau S, et al. Intensiﬁcation of HAART through the addi-
tion of enfuvirtide in naive HIV-infected patients with severe
immunosuppression does not improve immunologic response:
results of a prospective randomized multicenter trial (APOL-
LO-ANRS 130). 17th Conference on Retroviruses and Oppor-
tunistic Infections (CROI 2010); 2010.
7. Evering T, Mehandru S, Poles M, Racz P, Tenner-Racz K, Mohri
H, et al. Antiviral and immunologic effects of intensiﬁcation of
suppressive ART with maraviroc, a CCR5 antagonist. 17th
Conference on Retroviruses and Opportunistic Infections (CROI
8. Hatano H, Hayes T, Dahl V, Sinclair E, Lee T-H, Hunt P, et al.
Raltegravir intensiﬁcation in antiretroviral-treated patients
exhibiting a suboptimal CD4R T cell response. 17th Confer-
ence on Retroviruses and Opportunistic Infections (CROI 2010);
9. McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer
S, et al. Short-course raltegravir intensiﬁcation does not reduce
persistent low-level viremia in patients with HIV-1 suppression
during receipt of combination antiretroviral therapy. Clin Infect
Dis 2010; 50:912–919.
10. Sharkey ME, Teo I, Greenough T, Sharova N, Lazuriaga K,
Sullivan J, et al. Persistence of episomal HIV-1 infection inter-
mediates in patients on highly active antiretroviral therapy.
Nature Med 2000; 6:76–81.
11. Petitjean G, Al Tabaa Y, Tuaillon E, Mettling C, Baillat V, Reynes
J, et al. Unintegrated HIV-1 provides an inducible and func-
tional reservoir in untreated and highly active antiretroviral
therapy-treated patients. Retrovirology
12. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A,
Curlin ME, et al. HIV-infected individuals receiving effective
antiviral therapy for extended periods of time continually
replenish their viral reservoir. J Clin Invest 2005; 115:3250–
13. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H,
Deeks SG. T cell activation is associated with lower CD4R T
cell gains in human immunodeﬁciency virus-infected patients
with sustained viral suppression during antiretroviral therapy.
J Infect Dis 2003; 187:1534–1543.
14. Ramratnam B, Ribeiro R, He T, Chung C, Simon V, Vanderhoe-
ven J, et al. Intensiﬁcation of antiretroviral therapy accelerates
the decay of the HIV-1 latent reservoir and decreases, but does
not eliminate, ongoing virus replication. J Acquir Immune Deﬁc
Syndr 2004; 35:33–37.
15. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D,
Ferrante P, Wong JK. Productive infection maintains a dynamic
steady state of residual viremia in human immunodeﬁciency
virus type 1-infected persons treated with suppressive antire-
troviral therapy for ﬁve years. J Virol 2003; 77:11212–11219.
16. Kolber MA, Saenz MO, Tanner TJ, Arheart KL, Pahwa S, Liu H.
Intensiﬁcation of a suppressive HAART regimen increases CD4
counts and decreases CD8R T-cell activation. Clin Immunol
17. Gutierrez C, Diaz L, Hernandez-Novoa B, Vallejo A, Page C,
Lorente R, et al. Effect of the intensiﬁcation with a CCR5
antagonist on the decay of the latent reservoir and residual
viremia. 17th Conference on Retroviruses and Opportunistic
Infections (CROI 2010); 2010.
18. Wilkin T, Lalama C, Tenorio A, Landay A, Ribaudo H,
McKinnon J, et al. Maraviroc intensiﬁcation for suboptimal
CD4R cell response despite sustained virologic suppression:
ACTG 5256. 17th Conference on Retroviruses and Opportunis-
tic Infections (CROI 2010); 2010.
19. Buzon M, Massanella M, Llibre J, Esteve A, Puertas M, Palmer S,
et al. HIV-1 replication and immune dynamics are impacted by
raltegravir intensiﬁcation of HAART-suppressed patients. 17th
Conference on Retroviruses and Opportunistic Infections (CROI
20. Critchﬁeld JW, Lemongello D, Walker DH, Garcia JC, Asmuth
DM, Pollard RB, Shacklett BL. Multifunctional human immu-
nodeﬁciency virus (HIV) gag-speciﬁc CD8R T-cell responses in
rectal mucosa and peripheral blood mononuclear cells during
chronic HIV type 1 infection. J Virol 2007; 81:5460–5471.
21. Shacklett BL, Critchﬁeld JW, Lemongello D. Isolating mucosal
lymphocytes from biopsy tissue for cellular immunology as-
says. Methods Mol Biol 2009; 485:347–356.
22. Anton PA, Poles MA, Elliott J, Mao SH, McGowan I, Lenz HJ,
Chen IS. Sensitive and reproducible quantitation of mucosal
HIV-1 RNA and DNA viral burden in patients with detectable
and undetectable plasma viral HIV-1 RNA using endoscopic
biopsies. J Virol Methods 2001; 95:65–79.
23. Avettand-Fenoel V, Prazuck T, Hocqueloux L, Melard A, Mi-
chau C, Kerdraon R, et al. HIV-DNA in rectal cells is well
correlated with HIV-DNA in blood in different groups of
patients, including long-term nonprogressors. AIDS 2008;
24. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-
Shafer K, et al. Relationship between T cell activation and
CD4R T cell count in HIV-seropositive individuals with un-
detectable plasma HIV RNA levels in the absence of therapy.
J Infect Dis 2008; 197:126–133.
25. Swanson P, Huang S, Abravaya K, de Mendoza C, Soriano V,
Devare SG, Hackett J Jr. Evaluation of performance across the
dynamic range of the Abbott RealTime HIV-1 assay as com-
pared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1
MONITOR v1.5 using serial dilutions of 39 group M and O
viruses. J Virol Methods 2007; 141:49–57.
26. Tang N, Huang S, Salituro J, Mak WB, Cloherty G, Johanson J,
et al. A RealTime HIV-1 viral load assay for automated quanti-
tation of HIV-1 RNA in genetically diverse group M subtypes A-
H, group O and group N samples. J Virol Methods 2007;
27. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V,
et al. Biphasic decay kinetics suggest progressive slowing in
turnover of latently HIV-1 infected cells during antiretroviral
therapy. Retrovirology 2008; 5:107.
28. Kaiser P, Joos B, Niederost B, Weber R, Gunthard HF, Fischer M.
Productive human immunodeﬁciency virus type 1 infection
in peripheral blood predominantly takes place in CD4/CD8
double-negative T lymphocytes. JVirol2007; 81:9693–
29. Althaus CF, Gianella S, Rieder P, von Wyl V, Kouyos RD,
Niederost B, et al. Rational design of HIV-1 ﬂuorescent hydro-
lysis probes considering phylogenetic variation and probe
performance. J Virol Methods 2010; 165:151–160.
30. Fischer M, Joos B, Hirschel B, Bleiber G, Weber R, Gunthard
HF. Cellular viral rebound after cessation of potent antiretro-
viral therapy predicted by levels of multiply spliced HIV-1 RNA
encoding nef. J Infect Dis
31. Fischer M, Huber W, Kallivroussis A, Ott P, Opravil M, Luthy R,
et al. Highly sensitive methods for quantitation of human
immunodeﬁciency virus type 1 RNA from plasma, cells, and
tissues. J Clin Microbiol 1999; 37:1260–1264.
32. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G,
Hallahan CW, et al. Persistence of HIV in gut-associated
lymphoid tissue despite long-term antiretroviral therapy.
J Infect Dis 2008; 197:714–720.
33. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF,
et al. Dynamics of total, linear nonintegrated, and integrated
HIV-1 DNA in vivo and in vitro. J Infect Dis 2008; 197:411–
34. Phillips DM. The role of cell-to-cell transmission in HIV infec-
tion. AIDS 1994; 8:719–731.
35. Grossman Z, Feinberg M, Kuznetsov V, Dimitrov D, Paul W.
HIV infection: how effective is drug combination treatment?
Immunol Today 1998; 19:528–532.
Effect of RLG intensification on HIV in the gut Yukl et al. 2459